The editorial draws attention to neuropathy as an early diabetes complication associated with impaired quality of life and elevated mortality. Historical evidence cited by the authors linked neuropathy to subsequent renal impairment, and more recent prospective data have reinforced that relationship. Studies also indicate that cardiac autonomic neuropathy may already be detectable in people with prediabetes or increased prediabetes risk. In a comparison of people with prediabetes, those at increased risk of prediabetes and controls, both prediabetes and increased risk were associated with cardiac autonomic neuropathy independently of age. The authors caution, however, that these findings may point toward broader metabolic influences rather than short-term glycaemic variability alone.

Prospective evidence strengthens the connection between autonomic and somatic nerve involvement. Among people with diabetes who did not have diabetic sensorimotor polyneuropathy at baseline, established cardiac autonomic neuropathy independently predicted its later development under three complementary definitions during an average three-year follow-up. Reduced short-term heart-rate variability also identified people at increased risk and could potentially serve as a practical stratification marker. A separate cross-sectional study of people with type 2 diabetes and diabetic kidney disease found that cardiac autonomic neuropathy was more prevalent in advanced kidney disease and was associated with vitamin D deficiency and impaired heart-rate variability indices. Because that study was cross-sectional, it cannot establish that kidney disease, vitamin D deficiency or autonomic dysfunction caused one another.

Age also emerged as a major influence on the clinical pattern of sensory neuropathy. In a study of 442 patients with type 2 diabetes in a defined metropolitan area, mean age was 65.5 years and mean diabetes duration was 9.6 years. Researchers assessed pressure perception with a 10-g Semmes-Weinstein monofilament, vibration detection with a calibrated 128-Hz tuning fork and symptom reports obtained through three standardized questions about ulcers, persistent pain and lower-limb discomfort. Abnormal results were more frequent with the tuning fork, and the two methods frequently identified different patients. The findings indicate that standard screening tools are not interchangeable and suggest that a simple symptom questionnaire may complement objective testing in routine outpatient care.

Severe neuropathy can also complicate dental diagnosis and treatment, as illustrated by two case reports involving poorly controlled diabetes. A 14-year-old girl with 10 years of poorly controlled type 1 diabetes had marked oral disease, including gingivitis, angular cheilitis, extensive plaque, caries and pericoronaritis, yet showed amplified pain reactions during dental procedures despite adequate local anaesthesia. Quantitative sensory testing documented lower thresholds consistent with generalized sensory hyperexcitability. A 55-year-old man with long-term poor glycaemic control had severe generalized periodontitis, attachment loss, tooth mobility and multiple carious lesions, but reported little or no pain and underestimated the severity of his condition. Testing detected severe, partially maximal hypoesthesia. These cases are not prevalence estimates, but they demonstrate why dental assessment may require individualized strategies and close interdisciplinary cooperation.

Rare causes must also be considered when neuropathy is accompanied by hypoglycaemia. In one case, a 22-year-old woman experienced recurrent hypoglycaemia, numbness, tingling and burning limb pain. Investigations identified multiple radiculopathies and sensorimotor polyneuropathy, followed by a contrast-enhancing tumour near the junction of the body and tail of the pancreas. After laparoscopic distal pancreatectomy, her hypoglycaemia resolved and her neuropathy symptoms improved. The authors identify insulinoma as an uncommon possible cause of neuropathy and argue that early diagnosis is important. The single case does not establish how frequently pancreatic tumours produce this pattern, but it illustrates the value of considering endocrine causes when the clinical presentation is atypical.

Mechanistic research offers potential targets but does not yet amount to proven disease-modifying therapy. One review places oxidative stress at the center of diabetic nerve injury, connecting hyperglycaemia-activated pathways with mitochondrial dysfunction, endoplasmic reticulum stress and chronic inflammatory signaling. Other reviews examine emerging agents for painful diabetic neuropathy, including pilavapadin, an orally administered selective inhibitor of adapter protein-2-associated kinase 1, and vixotrigine, a broad-spectrum voltage-gated sodium-channel inhibitor. Experimental studies suggest possible effects of GLP-1 receptor agonists and SGLT2 inhibitors on neural damage, but the available clinical evidence comes mainly from small, short phase II randomized trials with inconsistent results for clinical and neurophysiological outcomes. Translation review similarly describes distal axon degeneration, impaired regeneration and the continuing absence of an established disease-modifying treatment.

Several studies in the collection examine early detection and risk prediction rather than therapeutic benefit. Current perception threshold testing showed moderate diagnostic accuracy for early C-fiber dysfunction in type 1 diabetes. A random-forest model identified age, diabetes duration, HbA1c, glycated serum protein and 25-hydroxyvitamin D as major predictors of diabetic polyneuropathy. In a propensity score-matched cohort, glycaemic variability was associated with the presence and severity of polyneuropathy independently of HbA1c, with systemic inflammation partly mediating the association. Mendelian randomization produced hypothesis-generating associations between selected phosphatidylcholine species and neuropathy risk. Additional reviews address Schwann-cell injury and potential roles for apoptosis, autophagy, pyroptosis, ferroptosis and necroptosis, as well as the integrated use of metabolic, renal, hepatic, inflammatory, thyroid and vitamin-related laboratory markers.

Interventions beyond medication remain under study. A meta-analysis of seven trials reported improved nerve conduction and glycaemic outcomes with dapagliflozin plus methylcobalamin, although the limited evidence base requires larger, more rigorous and more broadly generalizable trials. In a randomized study, high-intensity interval training and moderate-intensity continuous training both improved metabolic, inflammatory and neurological outcomes, with larger effects reported for high-intensity interval training. A network meta-analysis of antimicrobial dressings for diabetic foot ulcers ranked antibiotic-impregnated bone cement and silver dressings most favorably, while also identifying the need for direct comparative and cost-effectiveness studies. These findings cover different outcomes and interventions, so they should not be read as evidence that one approach universally outperforms the others.

The editorial ultimately argues for precision medicine in diabetic neuropathy because the condition varies in the nerve fibers affected, sensory manifestations, pain burden, mechanisms and individual course. Longitudinal sensory profiling has identified distinct trajectories of dysfunction, while magnetic resonance neurography has associated distinct sciatic-nerve structural patterns with different peripheral sensory phenotypes in type 2 diabetes. Quantitative sensory testing combined with C-fiber-oriented electrical stimulation also revealed that people with markedly impaired heat-pain perception could retain substantial electrically evoked pain responses, showing that loss of a sensory function does not necessarily mean loss of the corresponding excitable axons. The next step is to link mechanistic phenotypes to treatment response through robust prospective studies, targeted therapies and interventions that actually modify the disease rather than only its symptoms.

Subject of Research: Advances in diagnosing, stratifying and treating diabetic sensorimotor polyneuropathy

Article Title: Editorial: Frontiers in diagnostic and therapeutic approaches in diabetic sensorimotor neuropathy, volume II

Article References: Kender, Z., & Kempler, P. (2026). Editorial: Frontiers in diagnostic and therapeutic approaches in diabetic sensorimotor neuropathy, volume II. Frontiers in Endocrinology, 17, Article 2009636. https://doi.org/10.3389/fendo.2026.2009636

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.2009636

Keywords: diabetic neuropathy, sensorimotor polyneuropathy, cardiac autonomic neuropathy, sensory phenotyping, quantitative sensory testing, neuroimaging, neuropathic pain, precision medicine, diabetes complications, Editorial, Frontiers, diagnostic

The trial enrolled ninety patients with focal, mechanically caused peripheral nerve injuries — the kind produced by crush trauma, traction, lacerations, or chronic compression syndromes such as carpal tunnel and cubital tunnel disorder. Participants were randomly divided into three equal groups of thirty. One group underwent neurolysis surgery alone, a second took methylcobalamin tablets at 0.5 milligrams three times daily, and the third received both interventions. Every patient also followed the same standardized rehabilitation program, and all groups completed two consecutive thirty-day treatment courses before their sixty-day assessments.

The headline result was striking. The combination group achieved a total effective rate of 86.67 percent, meaning most patients in that group showed clear grade improvements on the Carroll Upper Extremity Function Test, a validated zero-to-ninety-nine scale of hand and arm function. By contrast, the neurolysis-only group reached 50.00 percent and the methylcobalamin-only group 53.33 percent. Ten patients in the combination arm were classified as fully cured, compared with four in the surgery group and five in the vitamin group, and only four combination patients remained in the ineffective category.

Objective electrophysiological measurements told the same story. Using nerve conduction studies, the researchers tracked motor conduction velocity, sensory conduction velocity, compound muscle action potential amplitude, and latency. While all three groups improved significantly from baseline, the combination group posted the largest gains across every parameter. Motor conduction velocity, for example, rose from roughly 38 meters per second at baseline to nearly 50 meters per second after treatment in the combined arm, versus gains of about six meters per second in each monotherapy group. Faster conduction and higher amplitudes signal restored axonal integrity and improved myelination — the biological substrate of real-world function.

Those electrical improvements translated into movement. Active and passive joint range of motion, measured with a goniometer, improved in all groups but soared in the combination arm: active range of motion climbed from about 10.5 degrees to 42.2 degrees, and passive range of motion from about 24 degrees to nearly 63 degrees, roughly double the gains seen in either monotherapy group. Pain scores on the Global Pain Scale, which covers clinical symptoms, emotional state, daily activities, and pain intensity, fell in every group, but the combination group recorded the lowest post-treatment scores in all four domains.

Blood tests added a biochemical dimension to the findings. The researchers measured serum levels of three inflammatory mediators — nuclear factor kappa B (NF-κB), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) — using enzyme-linked immunosorbent assays on fasting blood samples. All three markers dropped after treatment in every group, but the combination group achieved the deepest suppression: NF-κB fell to 13.76 micrograms per liter, TNF-α to 16.45 micrograms per liter, and IL-6 to 6.37 picograms per milliliter, all significantly lower than in either monotherapy arm. The trial also reported markedly lower rates of limb numbness, joint stiffness, chronic pain, and limb atrophy among combination patients.

The logic behind the synergy is biologically coherent. Neurolysis is a mechanical fix: surgeons meticulously free the injured nerve from scar tissue, adhesions, or fibro-osseous tunnels, restoring its ability to glide and re-establishing blood supply. But surgery alone does little to correct the hostile biochemical environment inside the damaged nerve, where inflammatory cascades perpetuate injury and stall regeneration. Methylcobalamin works from the opposite direction. As the neuroactive form of vitamin B12, it supports axonal regeneration, promotes myelin synthesis, sustains neuronal survival, and — as prior research has shown — inhibits NF-κB signaling and the downstream cytokines that drive neuropathic pain. What it cannot do is physically decompress a nerve trapped in constrictive scar tissue.

The trial’s methodology deserves attention. It was prospective, randomized, and evaluator-blinded: an independent statistician generated the allocation sequence using permuted blocks, assignments were concealed in sequentially numbered opaque envelopes, and all outcome assessments — functional testing, nerve conduction studies, range-of-motion measurements, pain scoring, and laboratory analyses — were performed by assessors blinded to group allocation. Patients and surgeons could not be blinded to surgery, but the intention-to-treat analysis and blinded data handling reduce the risk of detection bias. The sample size was determined a priori by power analysis, and baseline characteristics, injury etiologies, and severity were balanced across the three groups.

The authors are candid about limitations. The study was single-center, so results may not generalize to other populations or surgical teams. The follow-up window was only sixty days, which captures early recovery but says nothing about long-term durability, symptom recurrence, or late complications. The patient cohort mixed several injury subtypes, and subtle variations in surgical technique and rehabilitation adherence are unavoidable in clinical practice. Larger, multicenter trials with follow-up of twelve months or longer, homogeneous injury groups, and optimized methylcobalamin dosing regimens will be needed before the combined approach can be considered a standard of care.

Even with those caveats, the findings carry real weight for a condition that has long lacked rigorous comparative evidence. Traumatic peripheral nerve injuries affect an estimated 13 to 23 people per 100,000 each year, and the resulting disability and chronic pain impose heavy personal and economic costs. If the synergy holds up in larger trials, the message for clinicians would be straightforward: mechanical decompression and pharmacological neuroprotection are not competing strategies but complementary halves of the same problem. Freeing the nerve gives it room to heal; feeding it methylcobalamin helps it actually regenerate. The combination, this trial suggests, is more than the sum of its parts.

Subject of Research: Combined neurolysis surgery and methylcobalamin therapy for peripheral nerve injury recovery

Article Title: Synergistic efficacy of combined neurolysis and methylcobalamin in peripheral nerve injury: a randomized clinical trial

Article References: Hu, X., & Li, Z. (2026). Synergistic efficacy of combined neurolysis and methylcobalamin in peripheral nerve injury: a randomized clinical trial. Frontiers in Integrative Neuroscience, 20, Article 1747898. https://doi.org/10.3389/fnint.2026.1747898

Image Credits: AI Generated

DOI: 10.3389/fnint.2026.1747898

Keywords: peripheral nerve injury, neurolysis, methylcobalamin, vitamin B12, nerve conduction, inflammation, NF-κB, TNF-alpha, IL-6, randomized clinical trial, neuropathic pain, nerve regeneration

The case is striking not simply because the treatment worked, but because of how long the pain had been established. Neuropathic pain after spinal cord injury affects roughly half of all people living with such injuries, and it is among the most disabling consequences of the condition, undermining rehabilitation, psychological health, and quality of life. When pain persists for decades, the nervous system undergoes lasting changes in how it processes nociceptive signals, and many clinicians have assumed that such deeply entrenched pain becomes progressively harder to treat. The new report challenges that assumption, at least for one carefully selected patient, by showing a sustained, multidimensional response to neuromodulation more than three decades after the original injury.

The patient’s history was complex. The 1991 gunshot injury left metallic fragments lodged at the T12–L1 level of his spine, and he developed bilateral spastic paraparesis, meaning weakness and stiffness in both legs, markedly worse on the left side, along with muscle atrophy in his left lower limb and persistent sensory disturbances. Because no complete contemporary neurological examination following the standardized ISNCSCI framework was available from the time of injury, the clinical team could not reliably reconstruct a formal neurological level of injury or an AIS severity grade. Nevertheless, the pattern of his pain, burning and dysesthetic sensations across both lower extremities and the lower back, was clinically consistent with below-level neuropathic pain arising from the spinal cord injury itself.

Before recommending stimulation, the team worked to exclude other explanations. Electrodiagnostic testing found no evidence of peripheral neuropathy, and the patient had no history of diabetes. A lumbar CT scan showed no disc herniation or spinal canal stenosis that would require surgery, ruling out a mechanically correctable lesion that might account for his symptoms. Magnetic resonance imaging was impossible because of the retained bullet fragments. With a predominantly neuropathic pain phenotype, failure of prolonged conservative management, and no surgical target, the multidisciplinary team concluded that the pain was attributable to the old spinal cord injury and was refractory to further conservative treatment, making him a candidate for spinal cord stimulation.

The surgery itself was performed on February 15, 2024, under local anesthesia with the patient lying prone, which allowed the surgeons to test stimulation intraoperatively while the patient reported on coverage of his painful areas. Under fluoroscopic guidance, two epidural leads were positioned at the T8–T9 vertebral level, one slightly above the other, and connected to a Medtronic Inceptiv implantable pulse generator placed under the skin of the left gluteal region. The primary stimulation mode was differential target multiplexed, or DTM, stimulation, a paradigm designed to modulate pain-processing circuits with complex, interleaved signal patterns, supplemented by an individualized conventional tonic program and, later in follow-up, the device’s closed-loop stimulation function, which adjusts output in real time based on evoked compound action potentials recorded from the spinal cord.

The results were rapid and, so far, durable. About two months after implantation, the patient reported pain ranging from 0 to 2 out of 10, and by that point he had already discontinued pregabalin, duloxetine, clonazepam, and etoricoxib, the medications that had formed his pain regimen. At the formal 12-month assessment, his Visual Analog Scale score had fallen from 8 to 3, his Oswestry Disability Index had dropped from 60 percent to 30 percent, and his DN4 score, a screening measure of neuropathic pain features, had fallen from 8 to 2. His self-rated health on the EQ-VAS scale climbed from 40 out of 100 to 75, and his Hospital Anxiety and Depression Scale scores fell from 10 for both anxiety and depression to 3 and 4 respectively.

By 24 months, the gains had been maintained or extended. Pain intensity fell further to 2 out of 10, disability improved to an Oswestry score of 20 percent, self-rated health reached 80 out of 100, and the anxiety and depression scores declined to 2 and 3. The patient remained free of pain-directed medication, using occasional analgesics only for unrelated complaints such as headaches. He reported subjectively that his overall pain had decreased by more than 70 percent compared with his preoperative state, and he remained physically active. Residual burning pain in his feet and lower legs, particularly in the evenings, was managed through individualized reprogramming of the device. Crucially, no neurological deterioration, infection, lead migration, or other device-related complication occurred across the entire two-year follow-up period.

Why might stimulation still work after so many years of pain? The classical explanation for spinal cord stimulation is the gate-control model: activating large-diameter sensory fibers in the dorsal columns suppresses nociceptive transmission in the dorsal horn of the spinal cord. But contemporary research paints a far richer picture. Stimulation appears to modulate excitatory and inhibitory neurotransmission, alter dorsal horn neuronal activity, influence glial and neuroimmune signaling, and engage both ascending pain pathways and descending inhibitory systems that reach deep into supraspinal networks governing the sensory and emotional dimensions of pain. This distributed mechanism offers a plausible framework for why the patient’s improvements extended beyond pain intensity to psychological well-being and perceived health, although the authors are careful to note that a single case cannot establish mechanism.

The authors also place their observation in sobering context. A recent systematic review of spinal cord stimulation for pain after spinal cord injury identified only ten eligible studies comprising 43 patients, consisting mostly of case reports and small series with substantial heterogeneity in injury type, stimulation parameters, and outcome reporting. The certainty of that evidence is low, and favorable outcomes may be inflated by selection and publication bias. A meta-regression of stimulation outcomes found that longer pain duration was associated with reduced relief in univariable analysis, although no factor remained independently predictive in multivariable modeling. The Zagreb team therefore does not claim that chronicity is irrelevant to patient selection, only that very long pain duration does not invariably eliminate the capacity for a meaningful response.

The report carries clear limitations that the authors acknowledge candidly. Causal inference is impossible in a single patient, and some improvement could reflect nonspecific treatment effects or unmeasured factors. The Oswestry Disability Index is not validated specifically for spinal cord injury populations, so its improvement should be read as reduced pain-related disability rather than neurological recovery, and the patient’s fixed spastic paraparesis was unchanged throughout. The DN4 is a screening tool, not a quantitative measure of treatment response. Still, the case expands a very thin evidence base and suggests that symptom duration should be investigated as a modifier, rather than an absolute barrier, to neuromodulation in spinal cord injury pain. For the patient himself, the outcome was unambiguous: sustained relief, restored activity, freedom from daily medication, and, in his own assessment, a highly satisfactory result that endured through two full years of follow-up.

Subject of Research: Spinal cord stimulation for decades-old neuropathic pain after traumatic spinal cord injury

Article Title: Case Report: Beyond chronicity: sustained multidimensional response to spinal cord stimulation three decades after traumatic spinal cord injury

Article References: Blažević, A., Marčinković, P., Almahariq, F., Krušić, S., Dlaka, D., Chudy, D., Raguž, M., & Marinović, T. (2026). Case Report: Beyond chronicity: sustained multidimensional response to spinal cord stimulation three decades after traumatic spinal cord injury. Frontiers in Pain Research, 7, Article 1969355. https://doi.org/10.3389/fpain.2026.1969355

Image Credits: AI Generated

DOI: 10.3389/fpain.2026.1969355

Keywords: spinal cord stimulation, neuropathic pain, spinal cord injury, neuromodulation, chronic pain, case report, DTM stimulation, closed-loop stimulation, pain management, neurosurgery, disability, rehabilitation

The discovery centers on a protein called RGS4, which the team found acts as a kind of intracellular circuit governing whether pain sensitivity normalizes after an injury or becomes locked in place. In experiments described in the journal Science Signaling, the researchers blocked RGS4 in the dorsal root ganglia, clusters of sensory nerve cells that innervate the lumbar spinal cord. When they did so in experimental models of neuropathic pain, the nervous system recovered from its abnormal, hypersensitive condition. Conversely, when the scientists increased RGS4 levels, otherwise uninjured models became more sensitive to pain, demonstrating that the protein is not merely a passive marker of injury but an active driver of the transition to persistent pain.

The dorsal root ganglia are a logical place for such a switch to reside. These structures contain the cell bodies of sensory neurons that relay touch, temperature, and pain information from the body toward the spinal cord. Because they sit outside the blood-brain barrier’s protective envelope and outside the central nervous system proper, they are more accessible to targeted therapies than circuits deep within the brain. The Boston University team’s finding that RGS4 operates within these sensory nerve cells suggests that the maintenance of chronic pain may depend on molecular changes occurring in the periphery, rather than exclusively on rewiring within the spinal cord or brain.

RGS4 belongs to a family of regulator of G-protein signaling proteins, molecules that modulate how long intracellular signaling pathways remain active after a receptor on the cell surface is stimulated. By accelerating the deactivation of G-protein signaling, RGS proteins shape the intensity and duration of the messages a neuron sends. In the context of nerve injury, the new research indicates that RGS4 activity contributes to maladaptations, molecular and behavioral changes that keep sensory neurons unusually excitable. Venetia Zachariou, PhD, the Edward Avedisian Professor and chair of the department of pharmacology, physiology & biophysics at the school and the study’s corresponding author, explained that one reason pain may become chronic is that the sensory nerves themselves undergo molecular changes that keep them unusually sensitive.

To establish the protein’s role, the researchers used several groups of experimental models in which they could manipulate RGS4 in different ways. In some groups they removed the protein entirely, in others they reduced it specifically in sensory nerve cells, and in still others they increased its levels. This range of approaches allowed them to test whether the effects they observed were genuinely attributable to RGS4 rather than to compensatory developmental changes or off-target effects. They then assessed the functional consequences across a spectrum of chronic pain conditions, including peripheral nerve injury, postoperative pain, inflammatory pain, and chemotherapy-induced nerve damage, a breadth that strengthens the case that RGS4 is a general mechanism of pain chronification rather than a quirk of a single model.

The results carry particular weight because current treatments for chronic pain remain inadequate. Existing painkillers, including opioids such as morphine, largely mask the sensation of pain rather than addressing the biological processes that sustain it, and they can cause significant side effects, including the risk of dependence that has fueled a public health crisis. Many patients with neuropathic pain find little relief from any available medication. The Boston University team argues that the field needs therapies that interrupt the processes causing pain to persist in the first place, rather than simply dampening pain signals after chronic pain has already taken hold.

Zachariou emphasized that the findings point toward exactly that kind of intervention. Inhibition of RGS4, she noted, can be an effective way to manage neuropathic pain conditions and possibly other forms of chronic pain. Because the pathway can be manipulated in sensory nerve cells outside the brain and spinal cord, it may offer opportunities to develop more targeted treatments while potentially limiting effects elsewhere in the nervous system. That peripheral specificity matters enormously for drug development, since medications that act broadly on the central nervous system often produce sedation, cognitive effects, or addiction liability that limit their usefulness.

Importantly, the researchers also found that the main players controlling the maintenance of chronic pain in their experimental models are expressed in human nerve tissue as well. This conservation across species raises the possibility that RGS4 functions the same way in people, a critical prerequisite for translating the work into clinical therapies. While the study itself was conducted in experimental models, the presence of the relevant molecular machinery in human sensory neurons provides a plausible route from bench to bedside, and it suggests that biomarkers based on RGS4 activity could eventually help identify which patients are most likely to benefit from such treatments.

The broader significance of the work lies in its reframing of what chronic pain is. Rather than viewing persistent pain as simply a louder version of acute pain, the research supports a model in which chronic pain is a disease state sustained by specific, potentially reversible molecular adaptations in sensory neurons. Understanding the detailed mechanisms that control the transition from acute to chronic pain, and the maintenance of chronic pathological pain, the researchers argue, would be essential to guide the development of effective and safer medications. If the maladaptations can be reversed, as the RGS4 experiments suggest, then chronic pain may not be a permanent sentence but a treatable condition.

For patients, the hope is that future therapies built on this discovery could do what morphine and other current analgesics cannot: allow the nervous system itself to reset. Rather than simply masking pain after it becomes chronic, Zachariou said, the team hopes this work contributes to therapies that interrupt the biological processes that cause pain to persist in the first place. The findings appear online in Science Signaling, and the research was supported by National Institutes of Health funding including grants R01NS135775, R01NS117101, F31NS115318, and T32GM159592. As the opioid epidemic continues to highlight the dangers of symptomatic pain relief, mechanistic discoveries like this one offer a glimpse of a different future, one in which the circuits that keep pain alive are switched off at their source.

Subject of Research: The role of the RGS4 protein in dorsal root ganglia sensory neurons in the initiation and maintenance of chronic neuropathic pain

Article Title: BU researchers discover intracellular circuit responsible for chronic pain

Article References: BU researchers discover intracellular circuit responsible for chronic pain. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: chronic pain, neuropathic pain, RGS4, dorsal root ganglia, sensory neurons, Boston University School of Medicine, Science Signaling, peripheral nerve injury, pain chronification, drug targets, G-protein signaling, opioid alternatives

The story begins with microglia, the resident immune cells of the central nervous system. Under healthy conditions, microglia patrol the spinal cord and support tissue repair. After a nerve injury, however, many of them flip into a pro-inflammatory state, pumping out signaling molecules such as tumor necrosis factor, interleukin-6, and interleukin-1β that amplify pain signals. The researchers behind the new study, working with a mouse model of spared nerve injury, showed that this polarization shift is a central pathological node in neuropathic pain—and that coaxing microglia back toward an anti-inflammatory, pro-repair state can meaningfully relieve hypersensitivity to both mechanical touch and cold.

Their therapeutic tool of choice was aspirin-triggered resolvin D1, or AT-RvD1, a member of the specialized pro-resolving mediators. These are not conventional anti-inflammatory drugs that simply suppress the immune response; they are lipid messengers derived from omega-3 fatty acids that actively terminate inflammation and restore tissue homeostasis. AT-RvD1 itself is a 17R-hydroxylated derivative of docosahexaenoic acid, produced in the body when aspirin-acetylated cyclooxygenase-2 reroutes DHA metabolism toward resolution. Earlier work had hinted that AT-RvD1 could calm neuroinflammation in the spinal dorsal horn, but the molecular machinery it engaged remained obscure, and the molecule’s clinical promise was hobbled by rapid degradation in the bloodstream and the invasiveness of direct spinal injection.

To find the missing mechanism, the team turned to computational and molecular detective work. Mining a publicly available gene-expression dataset from a spinal nerve ligation model, they identified angiopoietin-like protein 4, or ANGPTL4, as a gene sharply upregulated in injured spinal cords. Subsequent experiments in BV2 microglial cells confirmed the pattern: inflammatory stimulation with lipopolysaccharide drove ANGPTL4 expression upward, and AT-RvD1 pulled it back down. The functional stakes became clear when the researchers manipulated ANGPTL4 directly. Silencing it with small interfering RNA suppressed pro-inflammatory cytokines, while overexpressing it—either in cultured cells or via adeno-associated virus in injured mice—fanned the inflammatory flames, pushed microglia toward the pro-inflammatory CD86-positive state, and blunted AT-RvD1’s analgesic effects. ANGPTL4, in short, was a linchpin.

The next question was how ANGPTL4 exerts its influence. Quantitative proteomics of treated microglia pointed the investigators toward propionate metabolism, and gas chromatography–mass spectrometry revealed that AT-RvD1 significantly raised propionate concentrations in the injured spinal cord. Immunoprecipitation coupled with mass spectrometry then identified SUCLG1, a key enzyme of the tricarboxylic acid cycle and propionate metabolism, as a physical binding partner of ANGPTL4. Co-immunoprecipitation and confocal imaging confirmed the interaction, and molecular docking revealed specific hydrogen bonds between the two proteins. The picture that emerged was elegant: ANGPTL4 binds SUCLG1 and shields it from ubiquitin-proteasome degradation, keeping the enzyme abundant. When AT-RvD1 suppresses ANGPTL4, SUCLG1 loses its protector, becomes polyubiquitinated, and is dismantled by the proteasome—shifting the spinal metabolic environment toward higher propionate, which the team showed is itself anti-inflammatory.

The metabolic logic checked out in both directions. Adding sodium propionate to AT-RvD1 treatment suppressed inflammatory proteins in microglia more strongly than the resolvin alone, and in injured mice the combination further reduced spinal inflammation and eased mechanical and cold allodynia. In a Transwell co-culture system pairing microglia with HT22 neurons, AT-RvD1-treated microglia passed along less inflammatory signaling to their neuronal neighbors, an effect amplified by propionate. The researchers had, in effect, charted a complete signaling axis—AT-RvD1 to ANGPTL4 to SUCLG1 to propionate—linking a lipid mediator of resolution to a metabolic switch that reprograms immune cells in the pain-processing centers of the spinal cord.

But a mechanism is only half a therapy. AT-RvD1 is fragile, degraded quickly in vivo, and getting it into the spinal cord conventionally requires intrathecal injection—a highly invasive procedure unsuited to repeated long-term dosing. The team’s solution was a liposomal nanocarrier decorated with MG1, a peptide that selectively recognizes activated microglia. Built from soy phosphatidylcholine, cholesterol, and a PEGylated lipid conjugated to the peptide, the resulting particles, dubbed A@Lipo-MG1, measured roughly 71 nanometers in diameter with a strongly negative surface charge, uniform size distribution, and spherical morphology confirmed by transmission electron microscopy. Nuclear magnetic resonance verified the peptide conjugation, and release studies showed a controlled profile, with more than half of the encapsulated AT-RvD1 released over four hours.

The targeting performance was striking. In cultured BV2 cells, rhodamine-labeled MG1-modified liposomes were taken up far more efficiently than unmodified versions, and the particles dampened inflammatory protein expression in a dose-dependent manner. In a laboratory model of the blood–spinal cord barrier, the modified liposomes crossed more readily, and pre-blocking with free MG1 peptide erased the advantage—strong evidence that the peptide was doing the recognition work. In injured mice, intravenously injected IR780-labeled MG1 liposomes lit up the spinal cord at six and twenty-four hours far more brightly than unmodified carriers, and confocal microscopy showed the fluorescent cargo accumulating inside Iba1-positive microglia in the spinal dorsal horn. Liquid chromatography–tandem mass spectrometry confirmed that A@Lipo-MG1 delivered the highest spinal AT-RvD1 concentrations of any formulation tested.

Functionally, the payoff was decisive. Intravenous free AT-RvD1 produced only a minimal analgesic effect, but the targeted liposomal formulation significantly alleviated mechanical hypersensitivity in the nerve-injured mice while reducing spinal mRNA and protein levels of interleukin-6, interleukin-1β, and tumor necrosis factor. Safety profiling showed no abnormalities in liver or kidney function biomarkers, and histological examination of heart, liver, spleen, lung, and kidney revealed no structural damage or inflammatory infiltration. The authors are candid about limitations: they did not resolve exactly how ANGPTL4 inhibits SUCLG1 ubiquitination, the precise binding interface remains unmapped, and only male mice were studied, leaving sex-dependent effects unexplored. Long-term pharmacokinetics in larger animals also await testing.

Even with those caveats, the study lands at a compelling intersection of immunology, metabolism, and nanomedicine. It elevates ANGPTL4 from a lipid-metabolism curiosity to a druggable node in spinal neuroinflammation, ties microglial polarization to a concrete metabolic handle in propionate, and demonstrates that a rationally designed, peptide-targeted liposome can ferry an unstable resolution mediator across biological barriers to the exact cells that need it. For the millions of patients whose pain outlasts their injuries and resists conventional drugs, the prospect of an intravenous therapy that does not merely mute pain signals but actively resolves the inflammation driving them is a genuinely new chapter—one that now has a defined molecular axis, a workable delivery vehicle, and a clear path toward translational testing.

Subject of Research: Targeted liposomal delivery of aspirin-triggered resolvin D1 to reprogram spinal microglia via the ANGPTL4-SUCLG1-propionate axis for neuropathic pain treatment

Article Title: AT-RvD1 liposomes effectively accumulate in spinal cord and reprogram microglia via ANGPTL4-SUCLG1-propionate axis for treating neuropathic pain

Article References: Wu, K., Gao, C., Fu, S., Li, Y., Li, Z., Han, X., Zhang, Y., Zhang, Y., & Wang, Y. (2026). AT-RvD1 liposomes effectively accumulate in spinal cord and reprogram microglia via ANGPTL4-SUCLG1-propionate axis for treating neuropathic pain. Materials Today Bio, 41, Article 103726. https://doi.org/10.1016/j.mtbio.2026.103726

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103726

Keywords: neuropathic pain, microglia, AT-RvD1, specialized pro-resolving mediators, ANGPTL4, SUCLG1, propionate, liposomes, nanomedicine, neuroinflammation, drug delivery, spinal cord

The headline finding is the sheer variability of the numbers. Among established long-term survivor cohorts, chronic pain prevalence ranged from 8.6 percent to 67.1 percent, a nearly eightfold spread that reflects differences in cancer type, treatment regimens, time since treatment, and how pain itself was measured. Head and neck cancer survivors, breast cancer survivors treated with surgery and radiotherapy, and patients who received neurotoxic chemotherapy all feature prominently in the evidence base. The authors caution that this heterogeneity is not simply statistical noise; it signals that chronic pain after cancer is not one condition but a family of conditions with different biological origins and different trajectories.

To understand why pain persists long after tumors are removed, the review turned to modern mechanistic classifications of chronic pain. Neuropathic pain, caused by direct damage or disease affecting the somatosensory nervous system, emerged as the most frequently reported mechanism across the included studies. This is biologically plausible: surgical dissection can sever peripheral nerves, radiation can injure nerve plexuses, and chemotherapeutic agents such as taxanes and platinum compounds are well known for causing peripheral neuropathy. In colorectal cancer survivors followed for up to eleven years in population-based registry studies, chemotherapy-induced neuropathy was associated with measurably worse quality of life, and in head and neck populations, radiation-induced nervous system complications were linked to persistent pain syndromes.

But the review also highlights a more controversial and scientifically intriguing category: nociplastic pain. Introduced into the International Classification of Diseases through the International Association for the Study of Pain’s ICD-11 framework, nociplastic pain arises from altered nociceptive processing despite no clear evidence of actual or threatened tissue damage or of a lesion in the somatosensory system. Some survivor populations in the review showed symptom profiles consistent with this mechanism, including patterns suggestive of central sensitization, in which the central nervous system becomes hyperexcitable and amplifies pain signals. Breast cancer survivor cohorts assessed with instruments such as the Central Sensitization Inventory showed that a subset of patients experience pain that cannot be explained by nerve damage or tissue injury alone.

Here the authors insert an important scientific caveat. Most mechanistic classifications in the reviewed studies were based on screening instruments and symptom questionnaires rather than diagnostic confirmation through quantitative sensory testing or other objective measures. Central sensitization, in particular, remains a construct that is easy to describe but difficult to verify. The certainty of evidence across the three outcome domains of prevalence, mechanism, and psychological impact was evaluated using the GRADE framework, and the authors are candid that the mechanistic evidence remains suggestive rather than definitive. This is a call to the research community: the field needs rigorous phenotyping studies that combine psychophysical testing, imaging, and longitudinal follow-up to move beyond symptom-based surrogates.

The psychological toll of persistent pain emerges as the review’s most consistent finding. Across the included studies, cancer survivors with chronic pain reported higher levels of anxiety, more severe depressive symptoms, greater emotional distress, and poorer quality of life than pain-free survivors. This comorbidity is not incidental. Decades of research on depression and pain comorbidity show that the two conditions share neurotransmitter pathways and amplify each other in a vicious cycle: pain disrupts sleep, sleep loss lowers pain thresholds and worsens mood, and depression reduces the motivation and energy needed for rehabilitation and self-management. Studies in the review found that post-traumatic stress symptoms arising from multiple cancer-related stressors predicted chronic pain, and that pain catastrophizing, the tendency to ruminate and magnify pain, was elevated in survivors with refractory postsurgical pain.

The functional consequences extend beyond mood. Research on working-age survivors has linked chronic pain to reduced health-related quality of life and to difficulties maintaining employment, a burden with obvious economic and social dimensions. For head and neck cancer survivors, pain often coexists with difficulties in swallowing, speaking, and shoulder function, compounding the impact on daily life. In breast cancer populations, persistent pain after treatment has been described as an underreported burden, with many patients never raising the issue during follow-up visits and clinicians rarely asking. The review’s implications section is direct: survivors should report ongoing pain and emotional symptoms, and survivorship care should include routine assessment of both.

Methodologically, the review is a model of transparency. The authors searched five major databases, PubMed, Scopus, Web of Science, Embase, and PsycINFO, registered their protocol prospectively in PROSPERO, appraised methodological quality with the Joanna Briggs Institute critical appraisal tools, and followed the PRISMA 2020 reporting guidelines. The included studies were predominantly cross-sectional and cohort designs covering a wide range of malignancies, from melanoma and testicular cancer to colorectal, breast, lung, and prostate cancers. No new primary data were generated; the analysis is entirely a synthesis of previously published work, with supporting data available in the article’s supplementary materials.

What should clinicians and patients take away from this body of evidence? First, chronic pain after cancer is common enough that it should be screened for systematically, not discovered only when a patient volunteers the information. The American Society of Clinical Oncology has long had a clinical practice guideline for managing chronic pain in adult cancer survivors, yet the review suggests that long-term care strategies remain lacking in practice. Second, because the mechanisms differ, treatment should differ: neuropathic pain may respond to different classes of medication than nociplastic pain, which often benefits from exercise, cognitive behavioral approaches, and centrally acting strategies. Multidimensional pain assessment, covering sensory qualities, psychological state, sleep, and function, is the practical corollary of the review’s mechanistic message.

Finally, the review identifies where science must go next. Stronger mechanistic research is needed to distinguish reliably between neuropathic, nociceptive, and nociplastic contributions in individual patients, and longitudinal studies should track how pain phenotypes evolve from the end of treatment into long-term survivorship. Emerging tools, including wearable devices capable of continuously monitoring pain-related parameters, may eventually help predict which patients are at highest risk before pain becomes entrenched. For now, the message for the growing global population of cancer survivors is clear: pain that persists after treatment is a medical condition in its own right, it is strongly linked to mental health, and it deserves the same systematic attention that surveillance for cancer recurrence already receives.

Subject of Research: Prevalence, mechanisms, and psychological outcomes of chronic pain in cancer survivors

Article Title: Prevalence, mechanisms, and psychological outcomes of chronic pain in cancer survivors: a systematic review with narrative synthesis

Article References: Myrzabay, Z., & Viderman, D. (2026). Prevalence, mechanisms, and psychological outcomes of chronic pain in cancer survivors: a systematic review with narrative synthesis. Journal of Cancer Survivorship. https://doi.org/10.1007/s11764-026-02138-7

Image Credits: AI Generated

DOI: 10.1007/s11764-026-02138-7

Keywords: cancer survivors, chronic pain, neuropathic pain, nociplastic pain, central sensitization, psychological outcomes, quality of life, systematic review, chemotherapy-induced neuropathy, survivorship care, depression, anxiety

The technique in question is high-frequency repetitive transcranial magnetic stimulation, or HF-rTMS, in which rapidly pulsed magnetic fields are applied over the primary motor cortex, the brain region that commands voluntary movement. Clinicians have long observed that this stimulation can improve motor recovery and dull neuropathic pain, but the two effects were almost always studied separately, and the cellular mechanism remained a black box. A team led by researchers at Xijing Hospital and the Fourth Military Medical University in Xi’an, China, set out to open that box, combining retrospective clinical data, a mouse model of spinal cord injury, single-nucleus RNA sequencing, electron microscopy, and viral gene therapy into one unusually complete causal chain.

The clinical evidence came first. The team reviewed records of 93 patients with spinal cord injury admitted between January 2018 and June 2025, of whom 40 received four consecutive weeks of HF-rTMS targeted at the left primary motor cortex at 10 Hz, 1,200 pulses per session. Compared with patients who did not receive stimulation, the treated group showed significantly greater gains on the modified Barthel index and manual muscle test, and, strikingly, only the stimulated group achieved a significant reduction in pain on the numerical rating scale. One therapy, two symptom domains, improved simultaneously in the same patients.

To understand why, the researchers turned to mice. They inflicted a standardized compression injury at the tenth thoracic vertebra, which produced lasting hind limb motor impairment measured by the Basso Mouse Scale, alongside mechanical allodynia and thermal hyperalgesia measured with von Frey filaments and a thermal testing apparatus. High-speed gait analysis on a glass floor added objective detail: injured mice walked more slowly, with worse coordination, and visibly shifted their weight away from painful hind paws. Five weeks of daily HF-rTMS, starting three days after injury, accelerated motor recovery, reversed both measures of pain hypersensitivity, and restored normal weight-bearing in the gait analysis. The mouse model faithfully reproduced the human motor-pain comorbidity, and the stimulation relieved both.

The mechanistic hunt then went molecular. The team sequenced roughly 90,000 individual nuclei from the primary motor cortex of uninjured, injured, and injured-and-stimulated mice, sorting them into nine major cell types. When they asked which biological processes were disrupted by injury and then reversed by stimulation, one theme dominated: mitochondrial energy metabolism, including oxidative phosphorylation, ATP synthesis coupled to electron transport, and aerobic respiration. And the reversal was strongest not in the excitatory neurons that send motor commands down the spinal cord, but in GABAergic inhibitory interneurons, the cells that keep cortical circuits balanced and prevent runaway excitation.

Mitochondria are the cell’s power plants, and their health depends on a constant cycle of fission and fusion. The master regulator of fission is a protein called dynamin-related protein 1, or Drp1, which pinches damaged mitochondria into smaller pieces so they can be repaired or cleared. Using transmission electron microscopy, the researchers identified GABAergic synapses in layer V of the motor cortex by their symmetric structure and pleomorphic vesicles, then measured the mitochondria inside those neurons. After injury, the mitochondria grew progressively larger and sparser, and their circularity, a marker linked to mitochondrial toxicity, climbed over five weeks. Western blots confirmed a rapid, sustained drop in Drp1 protein in the motor cortex, while the fusion proteins mitofusin 1 and 2 were untouched. The result was a bioenergetic crisis: ATP levels in the cortex fell sharply, and markers of damaged mitochondrial accumulation, VDAC-1 and Tom20, rose.

Here the story becomes remarkable in its specificity. Confocal imaging showed that the Drp1 loss occurred selectively within GAD67-positive GABAergic neurons, not in neighboring glutamatergic neurons, and that five weeks of HF-rTMS restored Drp1 expression only in that same inhibitory population. Electron microscopy confirmed that stimulation normalized mitochondrial size, density, and circularity in GABAergic neurons while leaving glutamatergic mitochondria largely unchanged. Cell-type-specific fluorescent staining for mitochondrial superoxide and the ATP synthase subunit ATP5A revealed elevated oxidative stress and diminished energy production confined to the inhibitory neurons, defects that both stimulation and Drp1 restoration reversed. Notably, the primary somatosensory cortex, a region deeply involved in pain perception, showed no such Drp1 response to stimulation, which may explain why clinical rTMS protocols aimed at the motor cortex tend to outperform those aimed at the sensory cortex for analgesia.

Correlation, however, is not causation, and this is where the study sets a new bar for neuromodulation research. Using adeno-associated viruses driven by the GAD67 promoter, the team overexpressed Drp1 exclusively in GABAergic neurons of the motor cortex. In injured mice, this single genetic intervention mimicked the entire therapeutic package: better motor scores from week two onward, reduced allodynia and hyperalgesia, improved gait, normalized mitochondrial ultrastructure, and ATP levels pushed back toward normal. Conversely, knocking Drp1 down in those same neurons worsened the injury phenotype and, most decisively, completely abolished every benefit of HF-rTMS. A pharmacological inhibitor of Drp1, Mdivi-1, likewise nullified the stimulation’s effects on motor function and pain. Drp1 in layer V GABAergic neurons of the motor cortex is thus both necessary and sufficient for the therapy to work, a bidirectional mediator of rTMS responsiveness.

Why would inhibitory interneurons be the vulnerable population? GABAergic neurons make up only about 15 to 20 percent of cortical cells but carry enormous metabolic demands, and spinal cord injury is known to reduce GABAergic inhibition in sensory and motor cortices, a disinhibition that contributes to both maladaptive motor plasticity and chronic pain. If Drp1 deficiency starves these neurons of ATP, their energy-intensive firing falters, cortical excitatory-inhibitory balance tips, and the motor-pain comorbidity follows. By restoring fission and bioenergetics in this microcircuit, HF-rTMS may re-arm the inhibitory system and, through the motor cortex’s descending connections to the periaqueductal gray and zona incerta, re-engage the brain’s endogenous pain-control machinery. The finding also carries a practical warning: common drugs that impair mitochondrial fission, including olanzapine, amitriptyline, escitalopram, and haloperidol, could theoretically blunt a patient’s response to rTMS, something clinicians may need to weigh when planning treatment.

The implications reach well beyond spinal cord injury. Mitochondria are not passive batteries but dynamic signaling hubs governing synaptic plasticity, calcium buffering, and cell survival, and this study provides the first cell-type-specific evidence linking a noninvasive brain stimulation therapy to the precise regulation of mitochondrial fission. The authors have launched a multicenter, double-blind, sham-controlled randomized clinical trial to convert the retrospective findings into guideline-grade evidence, and they caution that the molecular pathway connecting stimulation-induced neural activity to Drp1 transcription remains to be mapped. Still, the conceptual shift is profound: secondary neurodegeneration after central nervous system injury may be driven, at least in part, by a correctable bioenergetic failure in a defined set of cortical neurons, and the magnetic coil already sitting in rehabilitation clinics may be the tool that fixes it.

Subject of Research: Drp1-mediated mitochondrial dynamics in primary motor cortex GABAergic neurons as the mechanism of rTMS therapy after spinal cord injury

Article Title: Drp1 in M1 layer V GABAergic neurons orchestrates rTMS-mediated motor restoration and analgesia after spinal cord injury

Article References: Sun, X., Zhao, R., Zhang, K., Feng, X., Zhang, X., Yang, X., Li, Z., Tian, K., Kang, X., Lin, X., Gao, M., Hu, X., Lu, Y., Liang, Y., Luo, C., Wang, Y., & Yuan, H. (2026). Drp1 in M1 layer V GABAergic neurons orchestrates rTMS-mediated motor restoration and analgesia after spinal cord injury. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01857-2

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01857-2

Keywords: spinal cord injury, transcranial magnetic stimulation, Drp1, mitochondrial dynamics, GABAergic neurons, primary motor cortex, neuropathic pain, motor recovery, bioenergetics, single-nucleus RNA sequencing, neuromodulation, Mdivi-1

The research team, led by Hou-Ming Kan and colleagues working across institutions including Macau University of Science and Technology, the Affiliated Hospital of Xuzhou Medical University, and Peking University, cast an unusually wide net. They systematically searched five major databases, PubMed, Embase, the Cochrane Library, Web of Science, and Scopus, from their inception through July 1, 2025, hunting for randomized controlled trials that tested any neuromodulation technique against any form of neuropathic pain. Two reviewers independently extracted the data, and the team assessed the risk of bias in each trial using the Cochrane Risk of Bias 2 tool, the current gold standard for judging the methodological quality of randomized studies. The final harvest was remarkable: 115 randomized controlled trials evaluating 19 distinct neuromodulation techniques, spanning everything from implanted electrodes along the spinal cord to magnetic pulses aimed at the brain.

To make sense of this enormous body of evidence, the researchers turned to network meta-analysis, a statistical technique that has transformed how comparative medicine is done. Unlike a traditional meta-analysis, which can only pool trials that compare the same two treatments head to head, a network meta-analysis builds a web of comparisons across all trials simultaneously, allowing treatments that were never directly tested against each other to be ranked using both direct and indirect evidence. The team used Bayesian models, implemented in R 4.2.3 and Stata, to estimate the relative effectiveness of each technique. They then ranked the interventions using SUCRA, the surface under the cumulative ranking curve, a metric that assigns each treatment a score between zero and one hundred percent reflecting its probable position among all competitors.

Crucially, the authors did not stop at ranking. They recognized that a league table of treatments is only as trustworthy as the evidence beneath it, so they applied the Confidence in Network Meta-Analysis framework, known as CINeMA, which is built on the widely used GRADE system. This tool grades the certainty of each network estimate by considering factors such as the risk of bias in the contributing trials, the consistency between direct and indirect evidence, the precision of the estimates, and the possibility of publication bias. The conclusions were framed using a partially contextualised approach, meaning the authors weighed both the statistical strength of the findings and their practical importance for patients living with pain.

The headline result is that low-frequency spinal cord stimulation, often abbreviated LF-SCS, stood out as the neuromodulation technique with the most substantial supporting evidence for neuropathic pain, and the certainty of that evidence was rated as moderate. Spinal cord stimulation involves surgically implanting thin electrodes in the epidural space near the spinal cord, which deliver electrical pulses that interfere with pain signals ascending to the brain. Low-frequency stimulation, typically operating at rates below about 100 hertz, is the classic configuration that produces a mild tingling sensation known as paresthesia, and it has decades of clinical use behind it. What this new analysis adds is a formal, evidence-graded confirmation that among all the competing techniques, this established approach currently carries the strongest foundation of randomized trial data.

Close behind the leader, the analysis identified several other techniques with favorable analgesic effects, though the certainty of the evidence supporting them was rated as low. These included peripheral nerve stimulation, which targets individual nerves outside the brain and spinal cord; high-frequency spinal cord stimulation, which delivers rapid pulses at around 10 kilohertz and typically produces no tingling sensation at all; radiofrequency thermocoagulation, a technique that uses heat to selectively interrupt pain-carrying nerve fibers; dorsal root ganglion stimulation, which places electrodes on the clustered nerve-cell bodies where sensory fibers converge before entering the spinal cord; and two variants of pulsed radiofrequency, bipolar and high-voltage, which apply brief bursts of electrical energy to nerve tissue without generating destructive heat. The favorable signals for these methods are encouraging, but the authors are careful to note that low-certainty evidence means future research could materially change these conclusions.

Perhaps the most sobering findings concern the non-invasive transcranial techniques, the methods that aim electromagnetic or electrical stimulation at the brain from outside the skull. These include repetitive transcranial magnetic stimulation, which uses powerful magnetic pulses to excite neurons in the primary motor cortex or the dorsolateral prefrontal cortex, as well as transcranial direct current and alternating current stimulation, which pass weak currents through the scalp, and intermittent theta burst stimulation, a rapid patterned form of magnetic stimulation. The analysis found that these brain-directed approaches demonstrated only limited analgesic benefits, and the evidence behind even those modest effects was rated as low certainty. For patients drawn to the idea of pain relief without surgery, this is a reminder that non-invasive does not automatically mean proven, and the authors explicitly call for further studies before these techniques can be confidently recommended.

The significance of this work lies partly in what it exposes about the field itself. The authors point out that high-quality comparative evidence on the analgesic effects of different neuromodulation techniques has been lacking for most neuropathic pain subtypes, with the notable exception of well-defined conditions such as complex regional pain syndrome, a severe chronic pain condition that usually affects a limb after injury. This gap has left clinicians with limited guidance on optimal technique selection in most everyday clinical scenarios, where decisions about whether to implant a spinal cord stimulator, target a dorsal root ganglion, or try a course of transcranial magnetic stimulation have often rested on convention, local expertise, and device marketing rather than on graded comparative evidence. By assembling 115 trials into a single analytical framework, the review converts a fragmented literature into an interpretable map.

The methodological rigor of the study also deserves attention. Bayesian network meta-analyses rely on Markov Chain Monte Carlo sampling to explore the space of possible treatment effects, and the authors monitored convergence using standard diagnostics, including the Brooks-Gelman-Rubin statistic and potential scale reduction factors, to confirm that their models had stabilized. Standardized mean differences served as the effect measure, allowing trials that scored pain on different scales to be pooled on a common metric. The inclusion of credible intervals rather than simple confidence intervals reflects the Bayesian underpinning, expressing the range within which the true effect most plausibly lies. None of this statistical machinery guarantees truth, but combined with the CINeMA certainty grading, it gives readers a transparent account of how much confidence each conclusion deserves.

For patients and clinicians, the practical message is nuanced. The evidence now most strongly supports low-frequency spinal cord stimulation as a neuromodulation option for neuropathic pain, while several invasive alternatives show promise that awaits confirmation through better-designed trials. Non-invasive brain stimulation, despite its appeal, cannot yet be considered a reliably effective stand-alone therapy. The review, which received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors and declared no competing interests, is positioned by its authors as a basis for future research and clinical decision-making. In a field where implanted devices can cost tens of thousands of dollars and failed trials leave patients with scars and disappointment, an evidence-graded ranking of 19 techniques is more than an academic exercise. It is a compass for a specialty that has, until now, been navigating largely by instinct.

Subject of Research: Comparative efficacy of neuromodulation techniques for neuropathic pain

Article Title: Effects of neuromodulation techniques on neuropathic pain: a systematic review and network meta-analysis

Article References: Kan, H.-M., Hong, H.-Y., Hu, Y.-J., Qin, Y.-Y., Zhang, S., Bai, Y.-Y., Wang, C., Wang, R.-Y., Ding, X.-T., Shen, W., & Chen, L.-P. (2026). Effects of neuromodulation techniques on neuropathic pain: a systematic review and network meta-analysis. BMC Medicine. https://doi.org/10.1186/s12916-026-05300-1

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05300-1

Keywords: neuropathic pain, neuromodulation, spinal cord stimulation, network meta-analysis, dorsal root ganglion stimulation, pulsed radiofrequency, transcranial magnetic stimulation, peripheral nerve stimulation, randomized controlled trials, GRADE, pain medicine, BMC Medicine

The review, led by Xu-Ran Liao and colleagues at West China Hospital of Sichuan University, synthesizes nearly a decade of single-cell and single-nucleus RNA sequencing studies of the dorsal root ganglion, or DRG, across three major causes of neuropathic pain: traumatic peripheral nerve injury, diabetic painful neuropathy, and chemotherapy-induced neuropathy. Its central message is both striking and sobering. These conditions share broad biological processes, including neuronal state remodeling, disrupted glial support, context-dependent immune responses, and extracellular matrix reorganization, but they do not converge on a single conserved molecular program. In other words, there may be no one-size-fits-all target for chronic pain, and the search for one may explain why so many promising analgesics have failed in clinical trials.

The technological shift that made this insight possible is relatively recent. Conventional bulk RNA sequencing averages gene expression across an entire tissue, blurring the signals of rare but critical cell populations such as nociceptor subtypes and infiltrating immune cells. Single-cell RNA sequencing dismantles that limitation by profiling gene expression in individual cells, revealing that the DRG contains roughly 14 to 18 conserved sensory neuron subtypes across species. These include peptidergic nociceptors marked by Calca and Tac1, non-peptidergic nociceptors defined by Mrgprd and P2rx3, and myelinated low-threshold mechanoreceptors expressing Nefh and Ntrk2/3. Single-nucleus sequencing, which profiles RNA from isolated nuclei rather than whole cells, extends this approach to frozen human tissue and better captures the large sensory neurons that are often lost during enzymatic dissociation, though it sacrifices cytoplasmic and axonally localized transcripts.

Each method carries trade-offs that shape biological interpretation. Whole-cell dissociation can preferentially exclude large or fragile myelinated neurons and artificially induces stress-response genes such as Fos and Jun, while nuclear sequencing underrepresents messages enriched in distal axons. A recent single-soma deep-sequencing strategy combining laser capture microdissection with Smart-seq2 has pushed sensitivity further, detecting on average more than 9,000 unique genes per human DRG neuron, well beyond standard nuclear approaches. Spatial transcriptomics adds another dimension, preserving the anatomical arrangement of neuronal–glial units and immune niches that dissociation destroys. The review emphasizes that batch effects from differences in sequencing depth, tissue processing, and computational pipelines remain a significant obstacle to comparing results across laboratories, models, and species.

Beyond the neurons themselves, the single-cell era has transformed understanding of the DRG’s supporting cast. Satellite glial cells, once considered a homogeneous sheath wrapping each neuronal cell body, turn out to be molecularly diverse, with distinct subtypes preferentially associating with specific neuronal classes. Some express the potassium channel Kir4.1 and preferentially ensheathe nociceptors, while others, enriched in Fabp7, cluster around large mechanoreceptors. A subpopulation expressing Ugt8 and other galactosylceramide biosynthesis enzymes contributes to the structural integrity of the neuron–glia interface through lipid metabolism. Schwann cells, meanwhile, can revert to progenitor-like repair states after injury, and one recently identified stress-response subtype, marked by high neuropeptide Y expression, appears to coordinate tissue remodeling through osteopontin signaling. Resident macrophages exist along a spectrum of activation states rather than fitting the classical M1/M2 dichotomy, and mast cells have been shown to drive neurogenic inflammation through the Mrgprb2 receptor in selected nerve-injury models.

When the review compares the three pain etiologies, the contrasts are as informative as the similarities. Peripheral nerve injury triggers a partial loss of neuronal subtype identity, robust induction of the injury marker Atf3, and activation of regeneration-associated genes including Sprr1a and Gap43. Injured neurons secrete chemokines such as Ccl2 and Csf1, recruiting Ccr2-positive monocyte-derived macrophages into the ganglion, while satellite glial cells shift toward reactive gene expression and away from cholesterol biosynthesis, potentially starving neurons of lipid support for repair. The iPain atlas has additionally identified a senescence-like nociceptor state in chronic pain models, and senolytic treatment reduced pain-related behaviors in mice, though the authors caution that behavioral improvement alone does not prove the underlying transcriptional state is reversible.

Diabetic painful neuropathy, which affects up to half of all people with diabetes, tells a different story. Here the driver is chronic metabolic stress rather than mechanical trauma, and the neuronal changes reflect altered sensory coding: clusters associated with mechanical allodynia show upregulation of Fxyd7 and Atp1b1, implicating ionic dysregulation, while aberrant Mrgprd expression in non-peptidergic neurons suggests ectopic activation of cutaneous afferents. The most distinctive feature, however, is metabolic impairment of satellite glial cells. Reduced Ugt8 expression disrupts galactosylceramide biosynthesis, weakening lipid raft integrity and the metabolic coupling between glia and neurons. In human diabetic tissue, spatial profiling of Nageotte nodules, structures long associated with advanced neuropathy, revealed that they are composed mainly of SPP1-expressing satellite glial cells and non-myelinating Schwann cells accompanying dystrophic or sprouting sensory axons, providing a human pathological correlate of multicellular degeneration. Notably, macrophages in prediabetic mice can express Trem2 and Lgals3 and may actually delay sensory axon degeneration, a protective role that contrasts sharply with the pain-promoting macrophage response seen in some nerve-injury models and argues against indiscriminate anti-inflammatory strategies.

Chemotherapy-induced neuropathy adds yet another layer of complexity, because different drugs produce different pathologies. Paclitaxel causes widespread Camk1d upregulation across sensory neuron subtypes and prominent remodeling of C-low-threshold mechanoreceptor-like neurons, with functional knockdown experiments implicating Camk1d in thermal and cold hypersensitivity. Paclitaxel also suppresses Timp3 in satellite glial cells, disinhibiting metalloproteinase signaling involving Mmp14 and Adam17 and creating a pro-inflammatory microenvironment. Bortezomib, by contrast, drives an Atf3-dependent profibrotic program in satellite glial cells of male mice, producing collagen deposition that physically constricts sensory neurons, a response linked to macrophage–glial crosstalk and far less prominent in females, which instead showed relative enrichment of lipid metabolic programs. Sex, the review stresses, is a biological variable that pain research can no longer ignore.

These findings raise an obvious question: how well do mouse data translate to humans? Human DRG atlases built from single-nucleus sequencing, spatial transcriptomics, and single-soma deep sequencing show broad conservation of major sensory neuron classes but also reveal species-specific differences that may have undermined past analgesic development. Human nociceptors display a more continuous transcriptional spectrum than the discrete peptidergic and non-peptidergic clusters seen in mice, and some human-enriched populations, including a PIEZO2-high peptidergic subtype, lack clear murine counterparts. Markers such as TRPV1 and MRGPRD show broader, less discrete expression in human tissue, meaning a target that appears restricted to one nociceptor population in mice may be more diffusely distributed in humans. The clinical example of Nav1.7 illustrates the challenge: human loss-of-function variants in SCN9A cause congenital insensitivity to pain, yet selective Nav1.7 inhibitors have shown limited efficacy in trials, possibly because the channel’s expression is concentrated in only some nociceptor populations. Meanwhile, the Nav1.8 inhibitor suzetrigine has won regulatory approval for moderate-to-severe acute pain, though its efficacy in neuropathic pain remains under investigation.

The review’s authors are candid about the limits of the field. Most single-cell studies rely on single-time-point or repeated cross-sectional sampling, which cannot establish temporal progression or causality; pseudotime analyses order cells by transcriptional state but are not equivalent to biological time, and ligand–receptor inference predicts potential communication without proving spatial proximity or receptor activation. Human DRG tissue is available mainly from organ donors with incomplete pain phenotyping, and transcript abundance does not necessarily predict protein expression, neuronal excitability, or clinical pain. The path forward, the authors argue, requires integrating longitudinal and spatial transcriptomics with human genetics, functional validation in human sensory neurons, and clinical pharmacology. The DRG cannot be routinely biopsied in living patients, so surrogate approaches such as skin-biopsy molecular profiles, circulating extracellular vesicles, and organoid models will need development, even though current organoids resemble developmental rather than adult sensory tissue. The promise is real: a new generation of mechanism-based, cell-type-informed analgesics could finally match treatments to the specific cellular programs driving each patient’s pain. But the era of single-cell pain biology is, by its own architects’ admission, still in the hypothesis-generating stage, and the hardest experiments, the ones that prove causation in human tissue, lie ahead.

Subject of Research: Single-cell and single-nucleus transcriptomic profiling of dorsal root ganglion cell-state remodeling in neuropathic pain

Article Title: Single-cell and single-nucleus transcriptomics of the dorsal root ganglion in neuropathic pain: cell-state remodeling and translational prospects

Article References: Liao, X.-R., Zheng, H., Luo, J.-Y., & Zheng, B.-X. (2026). Single-cell and single-nucleus transcriptomics of the dorsal root ganglion in neuropathic pain: cell-state remodeling and translational prospects. Journal of Translational Medicine, 24(1), Article 1126. https://doi.org/10.1186/s12967-026-08732-8

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08732-8

Keywords: neuropathic pain, dorsal root ganglion, single-cell RNA sequencing, single-nucleus RNA sequencing, satellite glial cells, nociceptors, Schwann cells, diabetic neuropathy, chemotherapy-induced neuropathy, spatial transcriptomics, neuroimmune interactions, analgesic development

Postherpetic neuralgia arises when the varicella-zoster virus, the same pathogen responsible for chickenpox, reactivates years or decades later as shingles and damages sensory nerve fibers. In some patients the pain persists long after the characteristic blistering rash has healed, producing burning, stabbing, or electric shock-like sensations that can last for months or even years. While the condition is well recognized as a driver of reduced quality of life, sleep disturbance, and functional impairment, the authors of the new study note that its association with subsequent formal psychiatric diagnoses has remained underexplored, particularly in large and demographically varied populations. Their work was designed to fill that gap using real-world clinical data rather than small, single-center samples.

The methodology behind the study reflects the growing power of federated electronic health record networks. The researchers identified patients aged 18 and older who received a new diagnosis of herpes zoster between 2016 and 2023. Those diagnosed with postherpetic neuralgia within one month of the shingles diagnosis formed the exposed group, while patients who did not develop the complication formed the comparison group. Crucially, the team excluded anyone who had been diagnosed with any mental disorder before the shingles diagnosis or up to one month afterward, a design choice intended to ensure that the psychiatric outcomes being measured were genuinely new conditions rather than pre-existing ones. After propensity score matching, which balanced the two groups on demographic and clinical characteristics, each cohort contained exactly 15,454 patients.

Propensity score matching is a statistical technique widely used in observational research to mimic the conditions of a randomized trial. Because patients are not randomly assigned to develop postherpetic neuralgia, differences between the groups in age, sex, comorbidities, or healthcare utilization could otherwise confound the results. By matching patients on these covariates and checking balance with standardized mean differences, the investigators reduced the likelihood that the observed association between the pain condition and mental illness is an artifact of underlying differences between the populations. The outcome measure was the hazard ratio, a statistic that captures the relative rate at which new events occur in one group compared with another over the follow-up period.

The headline finding was a hazard ratio of 1.26 for any new mental disorder among patients with postherpetic neuralgia, with a 95 percent confidence interval of 1.12 to 1.42. In practical terms, at any point during the six months of follow-up, the PHN group developed psychiatric conditions at a rate roughly a quarter higher than the matched comparison group. When the researchers broke the results down by diagnostic category, two clusters stood out. Mood disorders, which include depression and bipolar spectrum conditions, showed a hazard ratio of 1.33, while anxiety-related conditions showed a hazard ratio of 1.26. Both confidence intervals excluded the null value of one, indicating that these elevations are unlikely to be due to chance alone.

Perhaps the most striking result emerged from the subgroup analyses. When the cohort was stratified by age, the association was strongest among younger adults. Patients aged 18 to 39 who developed postherpetic neuralgia had a hazard ratio of 1.82 for new mental disorders, with a confidence interval of 1.15 to 2.86, meaning their risk was nearly double that of matched peers without the pain condition. This finding challenges the common assumption that the psychiatric burden of shingles complications falls mainly on older adults, who experience the highest rates of the condition itself. Younger patients may face distinct vulnerabilities, including disruption of work, caregiving responsibilities, and social life during prime working years, as well as the psychological shock of developing a condition typically associated with aging.

Sex and race also shaped the pattern of risk. Female patients with postherpetic neuralgia showed a hazard ratio of 1.39 for new mental disorders, compared with 1.21 to 1.60 confidence bounds, suggesting a stronger association in women than in men. Across racial groups, elevated risks were observed for White patients at a hazard ratio of 1.26, Black patients at 1.44, and Asian patients at 1.97, the latter with a wide confidence interval of 1.06 to 3.67 reflecting a smaller number of events. The authors also examined herpes zoster vaccination status and the anatomical site of disease as stratification variables, underscoring their effort to identify which patient groups might benefit most from targeted psychological screening.

The biological plausibility of a link between chronic neuropathic pain and psychiatric illness is well supported by prior literature. Persistent pain activates stress-response systems, including the hypothalamic-pituitary-adrenal axis, and is associated with elevated levels of inflammatory signaling molecules such as interleukin-1, interleukin-6, and tumor necrosis factor alpha, all of which have been implicated in the pathophysiology of depression and anxiety. Chronic pain also disrupts sleep, limits physical activity, and erodes social engagement, each of which is an established risk factor for mood deterioration. In the specific case of postherpetic neuralgia, damage to sensory neurons can produce allodynia, a state in which normally painless stimuli such as clothing against the skin become excruciating, a symptom burden that patients frequently describe as among the most disabling aspects of the condition.

The study’s authors conclude that clinicians should consider early psychological evaluation and intervention for patients with postherpetic neuralgia, rather than treating the condition purely as a pain management problem. Because the elevated risk was measurable within six months of the shingles diagnosis, there is a defined window in which proactive screening for depression and anxiety could plausibly alter trajectories. The findings also add weight to public health arguments for shingles vaccination, since preventing herpes zoster and its most common chronic complication would avert the downstream psychiatric morbidity documented here. The research received support from Chung Shan Medical University Hospital, National Taichung University of Science and Technology, and Taiwan’s Ministry of Science and Technology, and was approved by the institutional review board of Chung Shan Medical University Hospital.

As with all observational studies, some caveats apply. The analysis relies on diagnostic codes recorded in electronic health records, which can vary in accuracy and completeness across institutions, and the six-month follow-up period cannot capture psychiatric outcomes that emerge later. Residual confounding is always possible in matched cohort designs, since factors such as pain intensity, medication use, and socioeconomic circumstances are imperfectly captured in claims-style data. Nevertheless, the scale of the TriNetX network, the rigorous exclusion of pre-existing mental illness, and the consistency of the signal across multiple demographic subgroups lend considerable credibility to the central conclusion: postherpetic neuralgia is not merely a sensory disorder but a condition with measurable consequences for mental health, and the youngest patients, who are least expected to suffer it, may bear the heaviest psychological toll.

Subject of Research: Association between postherpetic neuralgia and subsequent mental disorders in a large U.S. retrospective cohort

Article Title: Mental health impact of post-herpetic neuralgia: a retrospective cohort study from 15,454 patients using TriNetX network database

Article References: Yang, M.-H., Hsiao, Y.-P., Wang, Y.-H., Huang, L.-H., Du, Y.-S., & Wu, T.-J. (2026). Mental health impact of post-herpetic neuralgia: a retrospective cohort study from 15,454 patients using TriNetX network database. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08675-w

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08675-w

Keywords: postherpetic neuralgia, herpes zoster, shingles, mental disorders, depression, anxiety, mood disorders, TriNetX, retrospective cohort study, propensity score matching, neuropathic pain, varicella-zoster virus